Literature DB >> 20403553

Screening for psychiatric problems in the orofacial trauma setting.

Grant N Marshall1.   

Abstract

After facial trauma, a subset of patients develops mental health problems, particularly posttraumatic stress disorder (PTSD) and major depression. Early identification of patients who may be at risk for these disorders can facilitate referral for further psychiatric evaluation and possible treatment. Brief, easy-to-use screening tools are available to assist in the process of recognizing these individuals. This article provides a review of some of the most commonly used short screeners for PTSD and major depression. Incorporating information gleaned from these self-administered screeners into the routine evaluation of patients with facial trauma will help to address the mental health needs that are associated with orofacial injury.

Entities:  

Mesh:

Year:  2010        PMID: 20403553      PMCID: PMC2920222          DOI: 10.1016/j.coms.2010.01.007

Source DB:  PubMed          Journal:  Oral Maxillofac Surg Clin North Am        ISSN: 1042-3699            Impact factor:   2.802


  40 in total

1.  Psychological sequelae of facial trauma.

Authors:  J I Bisson; J P Shepherd; M Dhutia
Journal:  J Trauma       Date:  1997-09

2.  Derivation of the SPAN, a brief diagnostic screening test for post-traumatic stress disorder.

Authors:  S Meltzer-Brody; E Churchill; J R Davidson
Journal:  Psychiatry Res       Date:  1999-10-18       Impact factor: 3.222

3.  Anxiety sensitivity and PTSD symptom severity are reciprocally related: evidence from a longitudinal study of physical trauma survivors.

Authors:  Grant N Marshall; Jeremy N V Miles; Sherry H Stewart
Journal:  J Abnorm Psychol       Date:  2010-02

4.  Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients.

Authors:  A T Beck; R A Steer; R Ball; W Ranieri
Journal:  J Pers Assess       Date:  1996-12

5.  Assessment of a new self-rating scale for post-traumatic stress disorder.

Authors:  J R Davidson; S W Book; J T Colket; L A Tupler; S Roth; D David; M Hertzberg; T Mellman; J C Beckham; R D Smith; R M Davison; R Katz; M E Feldman
Journal:  Psychol Med       Date:  1997-01       Impact factor: 7.723

6.  Psychologic functioning and needs of indigent patients with facial injury: a prospective controlled study.

Authors:  Jennifer Lento; Shirley Glynn; Vivek Shetty; Joan Asarnow; Jianming Wang; Thomas R Belin
Journal:  J Oral Maxillofac Surg       Date:  2004-08       Impact factor: 1.895

7.  The development of acute post-traumatic stress disorder after orofacial injury: a prospective study in a large urban hospital.

Authors:  Shirley M Glynn; Joan R Asarnow; Robert Asarnow; Vivek Shetty; Karin Elliot-Brown; Edward Black; Thomas R Belin
Journal:  J Oral Maxillofac Surg       Date:  2003-07       Impact factor: 1.895

8.  A brief screening instrument to detect posttraumatic stress disorder in outpatient gynecology.

Authors:  Samantha Meltzer-Brody; Katherine Hartmann; William C Miller; Jewel Scott; Joanne Garrett; Jonathan Davidson
Journal:  Obstet Gynecol       Date:  2004-10       Impact factor: 7.661

9.  Psychological consequences of maxillofacial trauma: a preliminary study.

Authors:  A M Hull; T Lowe; M Devlin; P Finlay; D Koppel; A M Stewart
Journal:  Br J Oral Maxillofac Surg       Date:  2003-10       Impact factor: 1.651

10.  Posttraumatic stress disorder in the National Comorbidity Survey.

Authors:  R C Kessler; A Sonnega; E Bromet; M Hughes; C B Nelson
Journal:  Arch Gen Psychiatry       Date:  1995-12
View more
  2 in total

1.  Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial.

Authors:  Chun-Shin Chang; Christopher Glenn Wallace; Yen-Chang Hsiao; Chee-Jen Chang; Philip Kuo-Ting Chen
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

Review 2.  New Uses of AbobotulinumtoxinA in Aesthetics.

Authors:  Joel Schlessinger; Erin Gilbert; Joel L Cohen; Joely Kaufman
Journal:  Aesthet Surg J       Date:  2017-05-01       Impact factor: 4.283

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.